BR112017000464A2 - células gama delta t e uso das mesmas - Google Patents
células gama delta t e uso das mesmasInfo
- Publication number
- BR112017000464A2 BR112017000464A2 BR112017000464A BR112017000464A BR112017000464A2 BR 112017000464 A2 BR112017000464 A2 BR 112017000464A2 BR 112017000464 A BR112017000464 A BR 112017000464A BR 112017000464 A BR112017000464 A BR 112017000464A BR 112017000464 A2 BR112017000464 A2 BR 112017000464A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- gamma delta
- infection
- allogeneic
- cancer
- Prior art date
Links
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010362 Protozoan Infections Diseases 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4641—Fungal antigens, e.g. Trichophyton, Aspergillus or Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4647—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Abstract
trata-se de uma um método de preparação e uso de células t gama delta no tratamento alogênico ou autólogo de indivíduos que sofrem de infecção por vírus, infecção fúngica, infecção por protozoários e câncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201412175A GB201412175D0 (en) | 2014-07-09 | 2014-07-09 | Gamma T cells and uses thereof |
GB201415379A GB201415379D0 (en) | 2014-08-29 | 2014-08-29 | Gamma T cells and uses thereof |
GBGB1506423.1A GB201506423D0 (en) | 2015-04-15 | 2015-04-15 | Gamma delta T cells and uses thereof |
PCT/GB2015/051985 WO2016005752A1 (en) | 2014-07-09 | 2015-07-08 | Gamma delta t cells and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017000464A2 true BR112017000464A2 (pt) | 2017-11-07 |
Family
ID=53776892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017000464A BR112017000464A2 (pt) | 2014-07-09 | 2015-07-08 | células gama delta t e uso das mesmas |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170196910A1 (pt) |
EP (1) | EP3167050A1 (pt) |
JP (3) | JP2017524031A (pt) |
KR (1) | KR20170045205A (pt) |
CN (1) | CN107075480A (pt) |
AU (1) | AU2015287456A1 (pt) |
BR (1) | BR112017000464A2 (pt) |
CA (1) | CA2954546A1 (pt) |
EA (1) | EA201790010A1 (pt) |
IL (1) | IL249970B (pt) |
SG (1) | SG11201700134PA (pt) |
WO (1) | WO2016005752A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
US10532064B2 (en) * | 2014-08-12 | 2020-01-14 | The University Of Hong Kong | Biophosphonate compounds and gamma delta T cell-mediated therapy for treating epstein-barr virus-associated disorders |
EP3490675A4 (en) * | 2016-07-29 | 2020-07-29 | New York University | T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS |
EP3516043A1 (en) * | 2016-09-26 | 2019-07-31 | Tessa Therapeutics Pte. Ltd. | T cell expansion method |
TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
EP3743081A4 (en) | 2018-01-23 | 2021-12-01 | New York University | SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR |
KR20210069665A (ko) * | 2018-09-27 | 2021-06-11 | 포스포감, 인크. | 동종이계 감마/델타-t 세포의 확장 및 사용을 위한 방법 및 조성물 |
US20210388100A1 (en) | 2018-10-01 | 2021-12-16 | Adicet Bio, Inc. | Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors |
AU2019354395A1 (en) | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors |
WO2021016652A1 (en) * | 2019-07-29 | 2021-02-04 | The University Of Melbourne | METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS |
EP4045635A4 (en) * | 2019-10-17 | 2023-10-25 | The University of Hong Kong | METHODS FOR PREPARING EXOSOMES DERIVED FROM T-V LYMPHOCYTES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH EPSTEIN-BARR VIRUS |
US20230096410A1 (en) | 2020-03-06 | 2023-03-30 | Sorrento Therapeutics, Inc. | Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells |
EP4183871A1 (en) | 2021-11-23 | 2023-05-24 | Université d'Aix-Marseille | Process for preparing a composition comprising a combined cell population |
KR20230105166A (ko) * | 2022-01-03 | 2023-07-11 | 주식회사 이뮤노맥스 | 감마-델타 t 세포의 증식 배양 방법 |
TW202341971A (zh) | 2022-02-16 | 2023-11-01 | 法商普萊歐塞拉公司 | 使用car細胞及s1p受體調節劑之治療方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535002A (ja) * | 1999-01-28 | 2002-10-22 | パルメット ヘルス アライアンス,デー/ビー/エー パルメット リッチランド メモリアル ホスピタル | インビトロ活性化ガンマデルタリンパ球 |
AU2001248162B2 (en) * | 2000-04-03 | 2007-02-01 | Hemosol Lp. | Production of TcR gamma delta T cells |
KR100732206B1 (ko) | 2000-09-11 | 2007-06-27 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 티로신 키나제 억제제로서의 퀴놀리논 유도체 |
WO2006006720A1 (ja) | 2004-07-13 | 2006-01-19 | Medinet., Co.Ltd | γδT細胞の培養方法、γδT細胞及び治療・予防剤 |
ES2350895T3 (es) * | 2004-08-19 | 2011-01-28 | University College Cardiff Consultants Limited | Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia. |
WO2006017954A1 (en) * | 2004-08-19 | 2006-02-23 | University Of Bern | PREPARATION OF ANTIGEN-PRESENTING HUMAN Ϝδ T CELLS AND USE IN IMMUNOTHERAPY |
WO2007029689A1 (ja) | 2005-09-08 | 2007-03-15 | Medinet Co., Ltd. | 抗原提示細胞の活性化処理方法 |
JPWO2008152822A1 (ja) * | 2007-06-15 | 2010-08-26 | 株式会社メディネット | 医薬 |
-
2015
- 2015-07-08 CA CA2954546A patent/CA2954546A1/en not_active Abandoned
- 2015-07-08 KR KR1020177003596A patent/KR20170045205A/ko unknown
- 2015-07-08 AU AU2015287456A patent/AU2015287456A1/en not_active Abandoned
- 2015-07-08 EP EP15745544.5A patent/EP3167050A1/en active Pending
- 2015-07-08 WO PCT/GB2015/051985 patent/WO2016005752A1/en active Application Filing
- 2015-07-08 JP JP2017521620A patent/JP2017524031A/ja active Pending
- 2015-07-08 EA EA201790010A patent/EA201790010A1/ru unknown
- 2015-07-08 SG SG11201700134PA patent/SG11201700134PA/en unknown
- 2015-07-08 CN CN201580037383.2A patent/CN107075480A/zh active Pending
- 2015-07-08 BR BR112017000464A patent/BR112017000464A2/pt not_active Application Discontinuation
- 2015-07-08 US US15/325,012 patent/US20170196910A1/en not_active Abandoned
-
2017
- 2017-01-08 IL IL24997017A patent/IL249970B/en active IP Right Grant
-
2020
- 2020-04-27 US US16/859,954 patent/US20210030794A1/en not_active Abandoned
- 2020-07-03 JP JP2020115432A patent/JP2020172522A/ja active Pending
-
2023
- 2023-05-29 JP JP2023088259A patent/JP2023123437A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015287456A1 (en) | 2017-02-02 |
KR20170045205A (ko) | 2017-04-26 |
EP3167050A1 (en) | 2017-05-17 |
EA201790010A1 (ru) | 2017-05-31 |
JP2017524031A (ja) | 2017-08-24 |
JP2023123437A (ja) | 2023-09-05 |
JP2020172522A (ja) | 2020-10-22 |
CA2954546A1 (en) | 2016-01-14 |
US20170196910A1 (en) | 2017-07-13 |
US20210030794A1 (en) | 2021-02-04 |
WO2016005752A1 (en) | 2016-01-14 |
IL249970A0 (en) | 2017-03-30 |
IL249970B (en) | 2019-11-28 |
CN107075480A (zh) | 2017-08-18 |
SG11201700134PA (en) | 2017-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017000464A2 (pt) | células gama delta t e uso das mesmas | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
CY1123361T1 (el) | Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου | |
MX2019012233A (es) | Anticuerpos anti-sirpa. | |
EP3505620A4 (en) | 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID | |
CO2017002170A2 (es) | Terapia de combinación para tratar un paramixovirus | |
BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
CA2956871C (en) | Compounds active towards bromodomains | |
MX2022001105A (es) | Anticuerpos anti tigit. | |
CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
MX2020005187A (es) | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. | |
MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
BR112018012145A2 (pt) | partículas de entrega de pró-sabor | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
MX2022007522A (es) | Anticuerpos anti-cd27. | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2018015184A (es) | Métodos para el diagnóstico de infecciones bacterianas y virales. | |
WO2015153889A3 (en) | Materials and methods for the treatment of latent viral infection | |
EA201692477A1 (ru) | Композиции и способы применения для лечения метаболических расстройств | |
CL2017001110A1 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
BR112017008726A2 (pt) | usos de um extrato de fermento e de um exopolissacarídeo, e, composição cosmética. | |
BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |